

Table 12 - p-values of the Pairwise Comparisons of the cGMDs between Treatment Groups (Spjotvoll & Stoline test)

Treatment Groups	CTC 96 0%	CTC 96 0.05%	CTC 96 0.2%	CTC 96 1%
CTC 96 0%	-	0.046	0.019	0.010
CTC 96 0.05%	0.046	-	0.85	0.96
CTC 96 0.2%	0.019	0.85	-	0.98
CTC 96 1%	0.010	0.96	0.98	-

D. Effect of CTC 96 HPV-11 Treatment on Mouse Mortality

Regardless of the endpoint used, number of deaths ($p = 0.17$: Table 12) or length of survival ($p = 0.11$: Table 13), there were no differences among the treatment groups.

Table 13 - Mouse Mortality during the Experiment

Mouse Status at the end of the Experiment	CTC 96 0%	CTC 96 0.05%	CTC 96 0.2%	CTC 96 1%
Alive	10	11	8	12
Dead	2	1	4	0
Total	12	12	12	12

$p = 0.1745$: by Fisher-Freeman-Halton exact test

Table 14 - Mouse Survival (days) Summary Statistics

	Treatment Groups	Means	N	Standard Deviations	Lower Quartile	Median*	Upper Quartile
	CTC 96 0%	78.67	12	14.63	84.00	84.00	84.00
5	CTC 96 0.05%	83.167	12	2.89	84.00	84.00	84.00
	CTC 96 0.2%	69.83	12	24.52	57.50	84.00	84.00
	CTC 96 1%	84.00	12	0.00	84.00	84.00	84.00
10	All Groups	78.92	48	15.00	84.00	84.00	84.00

*p = 0.11: by Kruskal-Wallis test

E. Effect of CTC 96 HPV-11 Treatment on Mouse Weight Changes

There was no effect of HPV-11 treatment by CTC 96 on the weight gains of the mice during the experiment (p = 0.23).

Table 15 - Mouse Weight Changes (%) during the Experiment - Summary Statistics

	Treatment Groups	Means	N	Standard Deviations	Lower Quartile	Median*	Upper Quartile
	CTC 96 0%	6.19	9	9.57	3.33	8.28	12.76
	CTC 96 0.05%	13.12	8	3.89	12.32	14.16	15.62
	CTC 96 0.2%	15.77	6	7.71	11.48	11.77	24.80
20	CTC 96 1%	9.96	9	5.08	5.926	9.00	12.40
	All Groups	10.78	32	7.47	6.56	11.51	14.79

*p = 0.23: by Kruskal-Wallis test

The effect of CTC 96 on the infectivity of HPV-11 was evaluated in the human xenograft SCID mouse model. The results were analyzed for an effect of